CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade SEELOS THERAPEUTICS INC - SEEL CFD

0.5793
4.26%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.0312
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Seelos Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.6051
Open* 0.6169
1-Year Change* -9.17%
Day's Range* 0.5689 - 0.6169
52 wk Range 1.04-49.80
Average Volume (10 days) 424.31K
Average Volume (3 months) 13.35M
Market Cap 12.92M
P/E Ratio -100.00K
Shares Outstanding 9.57M
Revenue 1.55M
EPS -13.39
Dividend (Yield %) N/A
Beta 1.87
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 0.6051 0.1008 19.99% 0.5043 0.6338 0.4969
Mar 26, 2024 0.5015 0.0191 3.96% 0.4824 0.5339 0.4795
Mar 25, 2024 0.4836 -0.0327 -6.33% 0.5163 0.5163 0.4505
Mar 22, 2024 0.5028 -0.0015 -0.30% 0.5043 0.5193 0.4888
Mar 21, 2024 0.4893 -0.0449 -8.41% 0.5342 0.5540 0.4718
Mar 20, 2024 0.5458 -0.0681 -11.09% 0.6139 0.6204 0.5043
Mar 19, 2024 0.6508 0.2445 60.18% 0.4063 0.6963 0.3877
Mar 18, 2024 0.9079 -0.0884 -8.87% 0.9963 0.9963 0.8864
Mar 15, 2024 1.0063 -0.0500 -4.73% 1.0563 1.0563 0.9963
Mar 14, 2024 1.0363 -0.0300 -2.81% 1.0663 1.0763 1.0363
Mar 13, 2024 1.0663 -0.0400 -3.62% 1.1063 1.1063 1.0163
Mar 12, 2024 1.1163 0.0100 0.90% 1.1063 1.1463 1.0963
Mar 11, 2024 1.1563 -0.0200 -1.70% 1.1763 1.1963 1.1263
Mar 8, 2024 1.1363 0.0000 0.00% 1.1363 1.2463 1.1363
Mar 7, 2024 1.1263 0.0100 0.90% 1.1163 1.2463 1.1063
Mar 6, 2024 1.0963 0.1040 10.48% 0.9923 1.1063 0.9923
Mar 5, 2024 1.0263 -0.1100 -9.68% 1.1363 1.1363 1.0163
Mar 4, 2024 1.1763 -0.0200 -1.67% 1.1963 1.2263 1.1563
Mar 1, 2024 1.1863 -0.1400 -10.56% 1.3263 1.3263 1.1463
Feb 29, 2024 1.2463 0.0500 4.18% 1.1963 1.3163 1.1963

SEELOS THERAPEUTICS INC Events

Time (UTC) Country Event
Friday, May 17, 2024

Time (UTC)

12:00

Country

US

Event

Seelos Therapeutics Inc Annual Shareholders Meeting
Seelos Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0.375 0
Total Operating Expense 70.916 63.907 18.759 30.122 3.184
Selling/General/Admin. Expenses, Total 12.296 15.02 7.775 7.559 2.631
Research & Development 58.62 46.649 10.984 22.563 0.553
Unusual Expense (Income) 0 2.238
Operating Income -70.916 -63.907 -18.759 -29.747 -3.184
Interest Income (Expense), Net Non-Operating 0.107 -1.854 -0.119 0.013 -0.291
Other, Net -2.725 -0.287 -0.223 -21.521 0
Net Income Before Taxes -73.534 -66.048 -19.101 -51.255 -3.475
Net Income After Taxes -73.534 -66.048 -19.101 -51.255 -3.475
Net Income Before Extra. Items -73.534 -66.048 -19.101 -51.255 -3.475
Total Extraordinary Items
Net Income -73.534 -66.048 -19.101 -51.255 -3.475
Income Available to Common Excl. Extra. Items -73.534 -66.048 -19.101 -51.255 -3.475
Income Available to Common Incl. Extra. Items -73.534 -66.048 -19.101 -51.255 -3.475
Diluted Net Income -73.534 -66.048 -19.101 -51.255 -3.475
Diluted Weighted Average Shares 106.342 90.8901 44.7666 20.3088 3.08155
Diluted EPS Excluding Extraordinary Items -0.69148 -0.72668 -0.42668 -2.52378 -1.12768
Diluted Normalized EPS -0.69148 -0.70206 -0.42668 -2.52378 -1.12768
Revenue 0 0.375 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.336 0.808 0 0 0
Total Operating Expense 16.796 9.753 18.257 17.41 21.239
Selling/General/Admin. Expenses, Total 2.78 4.072 2.752 2.66 2.883
Research & Development 8.509 5.668 15.505 14.75 18.356
Operating Income -16.46 -8.945 -18.257 -17.41 -21.239
Interest Income (Expense), Net Non-Operating 0.076 0.06 0.04 0.034 0.014
Other, Net -13.112 -4.546 -0.44 -2.228 -0.047
Net Income Before Taxes -29.496 -13.431 -18.657 -19.604 -21.272
Net Income After Taxes -29.496 -13.431 -18.657 -19.604 -21.272
Net Income Before Extra. Items -29.496 -13.431 -18.657 -19.604 -21.272
Net Income -29.496 -13.431 -18.657 -19.604 -21.272
Income Available to Common Excl. Extra. Items -29.496 -13.431 -18.657 -19.604 -21.272
Income Available to Common Incl. Extra. Items -29.496 -13.431 -18.657 -19.604 -21.272
Diluted Net Income -29.496 -13.431 -18.657 -19.604 -21.272
Diluted Weighted Average Shares 131.916 112.52 107.067 106.69 106.069
Diluted EPS Excluding Extraordinary Items -0.2236 -0.11936 -0.17425 -0.18375 -0.20055
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.18185 -0.11925 -0.17425 -0.18375 -0.20055
Unusual Expense (Income) 5.507 0.013 0 0 0
Revenue 0.336 0.808
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 22.674 83.461 17.494 11.096 0.191
Cash and Short Term Investments 15.533 78.734 15.662 10.261 0.042
Cash & Equivalents
Prepaid Expenses 6.941 4.54 1.832 0.835 0.009
Other Current Assets, Total 0.2 0.187 0 0.14
Total Assets 22.746 83.5 17.494 11.096 0.191
Property/Plant/Equipment, Total - Net 0.072 0.039
Property/Plant/Equipment, Total - Gross
Accumulated Depreciation, Total
Other Long Term Assets, Total
Total Current Liabilities 25.158 8.287 7.429 10.778 4.897
Accounts Payable 3.626 1.693 1.887 0.796 2.22
Accrued Expenses 7.34 3.766 1.924 1.919 0.235
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 2.327 1.798 1.187 8.063 0
Total Liabilities 33.357 26.177 14.922 11.103 4.897
Total Long Term Debt 8.184 17.89 7.293 0 0
Other Liabilities, Total 0.015 0 0.2 0.325 0
Total Equity -10.611 57.323 2.572 -0.007 -4.706
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.107 0.105 0.054 0.027 0.003
Additional Paid-In Capital 204.026 198.428 77.68 56.027 0.097
Retained Earnings (Accumulated Deficit) -214.744 -141.21 -75.162 -56.061 -4.806
Total Liabilities & Shareholders’ Equity 22.746 83.5 17.494 11.096 0.191
Total Common Shares Outstanding 107.168 105.5 54.5359 27.0285 3.08155
Cash 15.533 78.734 15.662 10.261 0.042
Current Port. of LT Debt/Capital Leases 11.865 1.03 2.431 0 2.442
Long Term Debt 8.184 17.89 7.293
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 6.188 11.845 23.583 22.674 40.508
Cash and Short Term Investments 2.584 5.843 14.059 15.533 30.511
Cash 2.584 5.843 14.059 15.533 30.511
Prepaid Expenses 3.33 5.42 8.352 6.941 9.583
Total Assets 6.218 11.889 23.641 22.746 40.508
Property/Plant/Equipment, Total - Net 0.03 0.044 0.058 0.072 0
Total Current Liabilities 35.327 56.112 39.2 25.158 21.887
Accounts Payable 9.32 6.437 5.963 3.626 5.952
Accrued Expenses 6.371 5.635 5.659 7.34 4.048
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 15.573 12.34 11.62 11.865 10.655
Other Current Liabilities, Total 4.063 31.7 15.958 2.327 1.232
Total Liabilities 36.63 59.069 44.299 33.357 32.629
Total Long Term Debt 1.303 2.957 5.099 8.184 10.742
Long Term Debt 1.303 2.957 5.099 8.184 10.742
Other Liabilities, Total 0 0 0 0.015
Total Equity -30.412 -47.18 -20.658 -10.611 7.879
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.159 0.124 0.122 0.107 0.107
Additional Paid-In Capital 216.602 210.367 207.395 204.026 203.859
Retained Earnings (Accumulated Deficit) -247.173 -257.671 -228.175 -214.744 -196.087
Total Liabilities & Shareholders’ Equity 6.218 11.889 23.641 22.746 40.508
Total Common Shares Outstanding 159.503 124.188 121.811 107.168 107.168
Other Current Assets, Total 0.053 0.151 0.379 0.2 0.414
Total Receivables, Net 0.221 0.431 0.793
Accounts Receivable - Trade, Net 0.221 0.431 0.793
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -73.534 -66.048 -19.101 -51.255 -3.475
Cash From Operating Activities -61.604 -48.995 -20.913 -19.305 -1.581
Cash From Operating Activities
Non-Cash Items 9.147 18.46 2.733 25.089 0.193
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 0.011 0.01 0.011 0.016 0
Changes in Working Capital 2.783 -1.407 -4.545 6.861 1.701
Cash From Investing Activities
Capital Expenditures
Other Investing Cash Flow Items, Total
Cash From Financing Activities -1.597 112.067 26.314 29.524 1.365
Issuance (Retirement) of Stock, Net 0.564 125.618 15.26 29.524 0
Issuance (Retirement) of Debt, Net -1.888 -13.551 11.054 0 1.365
Net Change in Cash -63.201 63.072 5.401 10.219 -0.216
Financing Cash Flow Items -0.273
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -13.431 -73.534 -54.877 -35.273 -14.001
Cash From Operating Activities -10.348 -61.604 -48.514 -37.44 -17.045
Non-Cash Items 5.635 9.147 7.292 5.691 2.242
Cash Taxes Paid 0 0 0 0
Cash Interest Paid 0.114 0.011 0.011 0.009 0.004
Changes in Working Capital -2.552 2.783 -0.929 -7.858 -5.286
Cash From Financing Activities 8.874 -1.597 0.291 -0.043 0.083
Issuance (Retirement) of Stock, Net 10.16 0.564 0.564 0.083 0.083
Issuance (Retirement) of Debt, Net -1.286 -1.888 0 0 0
Net Change in Cash -1.474 -63.201 -48.223 -37.483 -16.962
Financing Cash Flow Items -0.273 -0.273 -0.126

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

SEELOS THERAPEUTICS INC Company profile

Seelos Therapeutics, Inc.
Industry: Pharmaceuticals (NEC)

300 Park Avenue
2nd Floor
NEW YORK
NEW YORK 10022
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,571.77 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

70,895.50 Price
+3.020% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading